Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
7
×
boston top stories
cancer
7
×
life sciences
national blog main
national top stories
roche
7
×
san francisco blog main
san francisco top stories
biotech
raleigh-durham blog main
raleigh-durham top stories
amgen
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
pfizer
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech ipos
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
deals
investing
merck
novartis
bridgebio
cancer drugs
What
cancer
drug
bio
ipo
life
medicines
roundup
address
admits
advantages
ago
alliance
annual
approval
approves
ash
bar
barcelona
big
biotechs
blood
blueprint
brings
bristol
broader
buy
calls
carries
certain
changing
classes
clinical
color
combinator
companies
company
conference
crispr
days
december's
Language
unset
7
×
Current search:
roche
×
" boston blog main "
×
unset
×
cancer
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone